Quarterly Result29 Oct 2025, 07:40 pm
Astec Lifesciences Reports Q2 FY26 Financial Results: EBITDA Loss Narrows to Rs. 5.6 Crore
AI Summary
Astec Lifesciences Limited has announced its financial results for the second quarter and half year ended September 30, 2025. The company reported a consolidated total income of Rs. 74.8 crore in Q2FY26, a decrease from Rs. 100.5 crore in Q2FY25. The company's consolidated EBITDA loss narrowed to Rs. 5.6 crore in Q2FY26, compared to a loss of Rs. 17.7 crore in Q2 FY25. The improvement in EBITDA was primarily driven by higher volumes and better gross margins in the Enterprise business. However, the contract manufacturing segment experienced a year-on-year revenue decline.
Key Highlights
- Astec reported a consolidated total income of Rs. 74.8 crore in Q2FY26, a decrease from Rs. 100.5 crore in Q2FY25.
- The company's consolidated EBITDA loss narrowed to Rs. 5.6 crore in Q2FY26, compared to a loss of Rs. 17.7 crore in Q2 FY25.
- The improvement in EBITDA was primarily driven by higher volumes and better gross margins in the Enterprise business.
- The contract manufacturing segment experienced a year-on-year revenue decline.
- For the half year ended September 30, 2025, the company reported a consolidated total income of Rs. 166.4 crore, compared to Rs. 170.8 crore in H1 FY25.